UNSPSC 51351614: Nilestriol or nylestriol

This classification denotes a steroidal estrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JA3B3IALU. European Medicines Agency schedules Nilestriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09288MIG. Nilestriol generally arises in the molecular formula C25H32O3.

The term NILESTRIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) NILESTRIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Nilestriol or nylestriol bears US NLM identifiers UMLS ID C0069173 and NCI Concept Code C80785. SMILES: CC12CCC3C(C1CC(C2(C#C)O)O)CCC4=C3C=CC(=C4)OC5CCCC5.

UNSPSC 51351614 Nilestriol or nylestriol is a Commodity code that captures pharmaceutical active ingredients and finished drugs, though recent state and local procurement activity under this code shows little activity specific to nilestriol itself. Instead, the code appears in broader multi-source pharmaceutical solicitations where state and local agencies procure generic pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The work involves manufacturers and distributors supplying packaged pharmaceuticals with specified National Drug Codes, strength, dosage form, and packaging configurations to authorized wholesalers serving state and local health systems, correctional facilities, and other government healthcare operations. Issuing bodies under this code include state procurement offices and multistate cooperative purchasing alliances administering contracts on behalf of multiple member jurisdictions and participating states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026. The RFP requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and submit detailed product information in standardized formats with pricing flexibility through flat-price, net-price, or WAC-minus structures. The contract runs two years for new responders with optional extensions, with awarded vendors becoming available to member states and local facilities by July 1, 2026, and vendors must carry specified insurance coverage including $5 million general liability, $2 million network security and privacy liability, and $2 million professional liability.